[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hematopoietic-system--cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hematopoietic-system--cancer":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,40,70],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100442419","hyperpolarized-129-xenon-imaging-in-adult-hematopoietic-cell-transplant-recipients-with-pulmonary-impairment-100442419",false,"NCT05041140","Hyperpolarized 129-Xenon Imaging in Adult Hematopoietic Cell Transplant Recipients With Pulmonary Impairment","Inclusion Criteria:\n\n\\- Allo-HCT recipients who are at least 18 years of age and have BOS (n=10 patients), BOS 0p (n = 10 patients), or cGVHD of a non-lung organ without evidence of pulmonary impairment (n = 5 patients).\n\nHealthy Cohort - Inclusion Criteria:\n\nWe will perform only XeMRI imaging on 10 healthy adult (18 years and older) volunteers with no medical issues for technical calibration of the XeMRI technology. Members of the study team may serve as healthy volunteers if they have no prior history of lung disease. These data will not be included as part of the analysis.\n\nExclusion Criteria:\n\n1. Participants unable to follow up at MD Anderson for routine clinical care\n2. Inability or unwillingness to give informed consent\n3. Relapsed disease or life expectancy less than 6 months at time of enrollment\n4. Severe claustrophobia precluding MRI imaging\n5. Active pulmonary infection\n6. Pregnant women",true,"ALL","18 Years",{"count":19,"type":20},25,"ESTIMATED","OBSERVATIONAL","This study is designed to measure the correlation of hyperpolarized 129-Xe magnetic resonance imaging (129-XeMRI) in allogeneic hematopoietic cell transplant (allo-HCT) recipients at MD Anderson Cancer Center (MDACC) who develop bronchiolitis obliterans syndrome (BOS) or BOS stage 0p (pulmonary impairment not meeting the definition for BOS, defined below) and controls with chronic graft-versus-host disease (cGVHD).\n\nThe primary objective of the study is to correlate 129-Xenon measures of ventilation, gas exchange, and pulmonary circulation with spirometric and quantitative CT measurements.\n\nA secondary objective is to determine whether measurement of 129-Xe MRI characteristics in patients with BOS stage 0p can predict BOS progression 6 months after enrollment.",[24,25,26],"Pulmonary","Pneumonia","Hematopoietic System--Cancer","RECRUITING","2026-04-29",{"date":30,"type":31},"2026-05-05","ACTUAL",{"date":33,"type":31},"2024-08-14",{"date":35,"type":20},"2027-07-20",{"name":37,"class":38},"M.D. Anderson Cancer Center","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":57,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":39},"100539182","exercise-and-health-counseling-in-pediatric-hematopoietic-stem-cell-transplantation-100539182","NCT06300515","Exercise and Health Counseling in Pediatric Hematopoietic Stem Cell Transplantation","Exercise Intervention in Childhood and Adolescence Hematopoietic Stem Cell Transplantation: The Henkō Trial","Henkō","Inclusion Criteria:\n\n* Age between 4 and 21 years.\n* Undergoing hematopoietic stem cell transplantation (HSCT) for cancer diagnosis in complete remission or without remission, in 3 recruiting Hospitals in Madrid\n* Undergoing treatment and follow-up in the same hospital.\n* Speaking Spanish.\n* Providing signed informed consent.\n\nExclusion Criteria:\n\n* Not being able to participate in the trial according to protocol.\n* Comorbidity or acute condition not associated with the diagnosis and that contraindicates the practice of physical exercise, such as severe deficiencies in the locomotor, neurological, cardiovascular and pulmonary systems.\n* Serious or chronic medical or psychiatric condition that may increase the risk associated with participation in the trial or that may interfere with the interpretation of the results and, in the opinion of the investigator in discussion with the team, makes having such condition inappropriate for entry to this study; inability to understand the study requirements.\n* Not being able to attend hospital visits to perform assessment tests, nor participate in the physical exercise and health counseling program as stipulated in the protocol.\n\nInability to understand the requirements of the study.","4 Years","21 Years",{"count":51,"type":20},48,"INTERVENTIONAL",[54],"NA","Thanks to medical advances, survival rates \\>5 years in children\u002Fadolescents undergoing hematopoietic stem cell transplant (HSCT) exceed 70%. However, these patients are at high risk of suffering sequelae associated with the underlying disease and\u002For the HSCT itself, which negatively affects their physical capacity. These patients also tend to spend too much time inactive, which further accelerates functional decline in addition to producing fatigue and impairing quality of life. Therefore, new strategies are needed to minimize the morbidity associated with HSCT. In this effect, although physical exercise represents an interesting adjuvant treatment option for HSCT, scientific evidence in this area is still scarce. Implementation of physical exercise intervention in pediatric HSCT units is challenging due to the lack of research on the effectiveness, affordability and accessibility of this type of intervention. Therefore, establishing the effectiveness of physical exercise under controlled conditions is an important step. The investigators therefore aim to assess the impact of a physical exercise and health counseling program, compared to health counseling only (control group), in pediatric patients with cancer undergoing HSCT on muscle strength (primary outcome), and several fitness\u002Ffunction, clinical burden (i.e., cardiac damage, treatment toxicities, health-related quality of life, among others) and biological variables (omics, blood immune phenotype, microbiome) (secondary outcomes). The investigators will also determine to what extent the benefits of this intervention are maintained over time. Additionally, the investigators will determine the intervention implementability in a real clinical situation in 3 different pediatric HSCT units.",[26],[58,59,60],"exercise","pediatric cancer","health counseling","2026-03-12",{"date":63,"type":31},"2026-03-17",{"date":65,"type":31},"2024-04-01",{"date":67,"type":20},"2026-12-31",{"name":69,"class":38},"Alejandro Lucia",{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":16,"minAge":77,"maxAge":17,"enrollmentInfo":78,"targetDuration":4,"studyType":52,"phases":80,"briefSummary":82,"conditions":83,"keywords":87,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":103},"100294904","phase-2-rct-of-olanzapine-for-control-of-civ-in-children-receiving-highly-emetogenic-chemotherapy-100294904","NCT03118986","RCT of Olanzapine for Control of CIV in Children Receiving Highly Emetogenic Chemotherapy","Randomized Controlled Trial of Olanzapine for the Control of Chemotherapy-induced Vomiting in Children Receiving Highly Emetogenic Chemotherapy","Planned receipt of HEC or cyclophosphamide ≥ 1 g\u002Fm2\u002Fday (≥ 33 mg\u002Fkg\u002Fday) for cancer treatment or autologous or allogeneic HSCT conditioning.81,82 Examples of HEC are: busulfan IV (myeloablative dosing), carboplatin ≥175mg\u002Fm²\u002Fdose, cisplatin ≥12mg\u002Fm²\u002Fdose, cytarabine ≥3g\u002Fm²\u002Fday, melphalan \\>140mg\u002Fm², methotrexate ≥12g\u002Fm²\u002Fdose and thiotepa ≥300mg\u002Fm²\u002Fdose.\n\nPlan for inpatient admission from administration of first study drug dose until 24 hours following administration of last study drug dose.\n\nBody weight of at least 12.5 kg\n\n2.5 to \\\u003C 18 years of age. Note that the minimum age requirement corresponds to an approximate body weight of 12.5 kg.\n\nSamples for all laboratory tests will be obtained within one week prior to administration of the first chemotherapy dose of the study chemotherapy block or the first HSCT conditioning dose:\n\n* Plasma creatinine within 1.5 times the upper limit of normal for age.\n* Amylase within age-appropriate limits\n* Plasma conjugated bilirubin within ≤ 3x upper limit of normal for age unless attributable to Gilbert's Syndrome\n* ALT ≤ 5x upper limit of normal for age\n\nBaseline ECG within the month prior to study drug administration without known clinically significant abnormalities including pathologic prolongation of QTc\n\nA plan for scheduled, round-the-clock receipt of ondansetron, granisetron or palonosetron for antiemetic prophylaxis during administration of chemotherapy or HSCT conditioning.\n\nNegative pregnancy test if female of childbearing potential\n\nPatients of childbearing potential must consent to use adequate contraception (males and females) or agree to practice abstinence\n\nParent or child able to speak a language in which the (modified Pediatric Adverse Event Rating Scale (PAERS) is available.\n\nOptional: Child participants in the optional assessment of nausea severity must be 4 to 18 years of age. Child and a parent\u002Fguardian must be English, Spanish or French-speaking. The Pediatric Nausea Assessment Tool58 (PeNAT) is validated in English-speaking children 4 to 18 years old with an English-speaking parent\u002Fguardian and has been translated into Spanish and French. The MAT is available in English, Spanish and French.","30 Months",{"count":79,"type":20},200,[81],"PHASE2","Chemotherapy-induced nausea and vomiting (CINV) are among the most bothersome symptoms during cancer treatment according to children and their parents. Most children receiving highly emetogenic chemotherapy (HEC), including those receiving hematopoietic stem cell transplant (HSCT) conditioning, experience CIV despite receiving antiemetic prophylaxis. Olanzapine improves CINV control in adult cancer patients, has a track record of safe use in children with psychiatric illness, does not interact with chemotherapy and is inexpensive. We hypothesize that the addition of olanzapine to standard antiemetics will improve chemotherapy-induced vomiting (CIV) control in children receiving highly emetogenic chemotherapy",[84,85,26,86],"Vomiting in Infants and\u002For Children","Nausea","Oncology",[88,89,90,91,92,93],"olanzapine","vomiting","children","adolescents","bone marrow transplant","supportive care","2025-10-03",{"date":96,"type":31},"2025-10-08",{"date":98,"type":31},"2017-08-10",{"date":100,"type":20},"2026-04",{"name":102,"class":38},"The Hospital for Sick Children",10]